Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

BACKGROUND: Although most non-small-cell lung cancer (NSCLC) patients with the echinoderm microtubule-associated protein-like 4 (EML4) – anaplastic lymphoma kinase (ALK) fusion gene – benefit from ALK tyrosine kinase inhibitors (ALK-TKIs), the efficacy of these drugs varies greatly among individuals...

詳細記述

保存先:
書誌詳細
主要な著者: Tanizaki, J, Okamoto, I, Takezawa, K, Sakai, K, Azuma, K, Kuwata, K, Yamaguchi, H, Hatashita, E, Nishio, K, Janne, P A, Nakagawa, K
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2012
主題:
Molecular Diagnostics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3322944/
https://ncbi.nlm.nih.gov/pubmed/22240786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.586
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料